Name | No. | For Patients with | Purpose |
---|---|---|---|
SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Non-Small Cell Lung Cancer | 18-33 | medically inoperable, early stage, high-risk centrally located non small cell lung cancer. |
The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy. |
DSSG Group: Lung
AbbVie M14-239
Name | No. | For Patients with | Purpose |
---|---|---|---|
AbbVie M14-239 | 18-49 | locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible) |
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). |
MK3475-671
Name | No. | For Patients with | Purpose |
---|---|---|---|
MK3475-671 | 17-37 | Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer |
To assess the efficacy and safety of Pembrolizumab (MK-3475) with platinum doublet chemotherapy as neoadjuvant/adjuvant therapy for participants With resectable stage IIB or IIIA non-small cell lung cancer. |